Inspire Investing LLC Purchases New Stake in Halozyme Therapeutics, Inc. $HALO

Key Points

• Inspire Investing purchased 28,340 Halozyme shares during the third quarter, valued at approximately $3.13 million. Institutional investors collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with revenue up 47.7% year over year to $481 million and EPS of $2.28, exceeding analyst estimates of $1.79. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Insiders sold 125,852 shares worth $13.5 million over the past 90 days, while analyst sentiment remains broadly positive with a consensus rating of “Moderate Buy” and an average price target of $99.55.

Inspire Investing LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 28,340 shares of the biopharmaceutical company's stock, valued at approximately $3,129,000.

Several other institutional investors also recently bought and sold shares of HALO. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics in the second quarter worth $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $28,000. Quantbot Technologies LP acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $30,000. CoreCap Advisors LLC boosted its position in Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 150 shares during the period. Finally, Caitlin John LLC purchased a new stake in Halozyme Therapeutics during the 2nd quarter worth $44,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew Posard sold 18,996 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director directly owned 58,839 shares of the company's stock, valued at $6,339,313.86. This represents a 24.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock valued at $13,538,046 in the last ninety days. Insiders own 2.50% of the company's stock.

Halozyme Therapeutics Trading Up 0.9%

NASDAQ HALO opened at $125.63 on Friday. The stock has a market cap of $14.26 billion, a P/E ratio of 37.50, a PEG ratio of 0.47 and a beta of 0.88. The company's fifty day simple moving average is $111.37 and its 200-day simple moving average is $87.03. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $126.23.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period last year, the business earned $1.54 EPS. The business's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 8.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a "neutral" rating in a research report on Thursday, October 8th. Citigroup reiterated a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Zacks Research upgraded Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 13th. Finally, TD Cowen raised their target price on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.55.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.